Form 4 for NAMS NewAmsterdam Pharma Co N.V.
Accepted 2024-10-01 00:00:00 ET · period of report 2024-09-27 · accession 0000950170-24-110955 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2024-10-01 | 2024-09-27 | NAMS | Kooij Louise Frederika | CAO | M - OptEx | — | +45.0K | 45.0K | New | — |
| D | 2024-10-01 | 2024-10-01 | NAMS | Kooij Louise Frederika | CAO | S - Sale+OE | $15.72 | -45.0K | 0 | -100% | -$707.4K |
| D | 2024-10-01 | 2024-09-27 | NAMS | Kooij Louise Frederika | CAO | M - OptEx | $0.00 | -45.0K | 168.1K | -21% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Ordinary Shares | 2024-09-27 | M | A | 45,000 | — | 45,000 | D | — | — | (F1) The exercise price of the option is EUR 1.16392. (F2) The securities were previously held indirectly by the Reporting Person through LouFre Management B.V. ("LouFre") for the benefit of the Reporting Person. The Reporting Person had the sole pecuniary interest in the securities. |
| 2 | Common | Ordinary Shares | 2024-10-01 | S | D | 45,000 | $15.72 | 0 | D | — | — | |
| 3 | Derivative | Option (right to buy) | 2024-09-27 | M | D | 45,000 | $0.00 | 168,073 | D | — · — to 2031-07-06 | 45,000 Ordinary Shares | (F2) The securities were previously held indirectly by the Reporting Person through LouFre Management B.V. ("LouFre") for the benefit of the Reporting Person. The Reporting Person had the sole pecuniary interest in the securities. (F1) The exercise price of the option is EUR 1.16392. (F3) The option was granted on November 22, 2022 to replace an option originally granted on July 6, 2021 which was cancelled in connection with the consummation of NewAmsterdam Pharma Company N.V.'s business combination with Frazier Lifesciences Acquisition Corporation. 60,879 of the shares underlying the option immediately vested on the grant date. 25% of the remaining shares underlying the option vested on January 1, 2021, the one-year anniversary of vesting start date, with the remaining shares vesting in equal monthly installments thereafter for three years, subject to the Reporting Person's continued service through each such date. |